When a business resolution isn’t possible, the choice of forum shapes everything that follows. This recorded webcast compares mediation, litigation, and arbitration across the factors that matter most — timing, cost, confidentiality, discovery, motion practice, and appellate rights — and compares the strategic advantages and trade-offs each path presents.
Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration and licensing dispute across its full lifecycle to explore how contract language, forum selection, and science shape leverage, timing, proof, and outcomes.
Our partners share insights on the trends shaping dealmaking in the Life Sciences sector—and what to watch in the months ahead. September 2026 · Life Sciences Featuring insights from Ryan Murr, Sebastian Fain, and Branden Berns. DEAL ACTIVITY What’s driving deal activity in the sector right now? Murr: Life Sciences deal volume is up substantially,…
On August 31, 2026, the White House announced most-favored-nation (“MFN”) pricing agreements with nine additional pharmaceutical manufacturers: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements bring the total number of manufacturers with MFN deals to 26, which the White House says covers 89 percent of the branded drug market.
This article describes the current state-of-play with MFN and key deal drafting considerations. Life sciences dealmaking is running at a record pace — straight into a pricing regime that is still being written. According to Gibson Dunn’s July biopharma M&A survey, the first half of 2026 saw 13 announced acquisitions of public biopharma targets ranging…
Corp Fin leadership has signaled that staff time may be better spent listening to earnings calls than reviewing routine shelf filings, and a recent comment letter exchange shows why. For life sciences companies, whose calls routinely cover program-level spend, clinical data, and cash runway, inconsistencies between the call and the filings are a potential source of staff comments.
In the first six months of 2026, acquirers announced 13 qualifying acquisitions of public biopharma targets worth $66.6 billion in upfront consideration. This survey examines that period and the surge within it: what is driving it, how the deals are structured, and what it means for the parties negotiating the next one. Focusing on the…
